Browsing by Author "Djuric, Dragan M. (36016317400)"
Now showing 1 - 20 of 36
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication A prospective, randomized, double-blind, placebo-controlled trial of polyphenols on the outcomes of inflammatory factors and oxidative stress in patients with type 2 diabetes mellitus(2022) ;Grabež, Milkica (36677076800) ;Škrbić, Ranko (6506440995) ;Stojiljković, Miloš P. (7003831355) ;Vučić, Vesna (14049380100) ;Grujić, Vesna Rudić (36677183800) ;Jakovljević, Vladimir (56425747600) ;Djuric, Dragan M. (36016317400) ;Suručić, Relja (57193932313) ;Šavikin, Katarina (23098139900) ;Bigović, Dubravka (36083929700)Vasiljević, Nada (9744452100)Background: Type 2 diabetes mellitus (T2DM) is commonly associated with hyperglycemia, dyslipidemia, oxidative stress and inflammation which are well known cardiovascular risk factors. Pomegranate peel polyphenols have a proven hypolipemic, antioxidant and anti-inflammatory activity. However, there is a lack of clinical studies that would confirm its antioxidant and anti-inflammatory effects in diabetic patients. The potential of pomegranate peel extract (PoPEx) to counteract inflammation and oxidative stress in T2DM patients was investigated. For this purpose, a randomized, double-blind placebo-controlled study involving adult T2DM patients treated with PoPEx or placebo for eight-weeks was conducted. Methods: Patients were randomly divided into two groups: The first group (n = 30) received capsules containing PoPEx 250 mg twice daily, while the placebo group (n = 30) received placebo capsules twice daily. Plasma concentration of inflammatory factors (interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) and high sensitivity C reactive protein (hsCRP)), oxidative stress biomarkers (thiobarbituric acid reactive substances (TBARS), nitrites (NO2 -), superoxide anion radical (O2 -), hydrogen peroxide (H2O2), total antioxidant capacity (TAC)), homocysteine and lipid profile were analyzed. Results: The PoPEx treatment showed a significant reduction of inflammatory factors (IL-6, TNF-α, hsCRP), oxidative stress biomarkers (TBARS, NO2 -, O2 -) and homocysteine, while the TAC was increased. Moreover, a significant improvement in lipid profile was observed in the PoPEx group. Additional analysis showed a significant inverse correlation between the decrements of all measured inflammatory markers and TAC in the PoPEx group. Conclusions: The study demonstrated that eight-week-long PoPEx administration had favorable effects on inflammatory status and oxidative stress biomarkers in diabetic patients. © 2022 The Author(s). - Some of the metrics are blocked by yourconsent settings
Publication Acute effects of nandrolone decanoate on cardiodynamic parameters in isolated rat heart(2016) ;Nikolic, Tamara R. (56425849500) ;Zivkovic, Vladimir I. (55352337400) ;Srejovic, Ivan M. (55754581700) ;Radovanovic, Dragan S. (56400605600) ;Jeremic, Nevena S. (56609154900) ;Jevdjevic, Maja D. (57211562230) ;Djuric, Dragan M. (36016317400)Jakovljevic, Vladimir Lj. (56425747600)Despite worldwide use of anabolic steroids in last decades, there is still contradictory information about their acute influence on myocardium. The aim of this study was to examine the acute effects of nandrolone decanoate (ND) on cardiodynamics and coronary flow in isolated rat heart. The hearts of male Wistar albino rats (n = 48, 12 per group, age 8 weeks, body mass 180-200 g) were excised and perfused according to the Langendorff technique at gradually increased coronary perfusion pressures (40-120 cmH2O). After the control sets of experiments, the hearts in different groups were perfused with different doses of ND (1, 10, or 100 µmol/L separately). Using a sensor placed in the left ventricle, we registered maximum and minimum rate of pressure development in the left ventricle (dP/dtmax and dP/dtmin), systolic and diastolic left ventricular pressure (SLVP and DLVP), and heart rate (HR). Coronary flow (CF) was measured flowmetrically. The results clearly show the depression in cardiac function caused by higher doses of ND. The highest concentration of ND (100 µmol/L) induced the most deleterious impact on the myocardial function and perfusion of the heart (coronary circulation), which could be of clinical significance. © 2016, Canadian Science Publishing. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Acute effects of nandrolone decanoate on cardiodynamic parameters in isolated rat heart(2016) ;Nikolic, Tamara R. (56425849500) ;Zivkovic, Vladimir I. (55352337400) ;Srejovic, Ivan M. (55754581700) ;Radovanovic, Dragan S. (56400605600) ;Jeremic, Nevena S. (56609154900) ;Jevdjevic, Maja D. (57211562230) ;Djuric, Dragan M. (36016317400)Jakovljevic, Vladimir Lj. (56425747600)Despite worldwide use of anabolic steroids in last decades, there is still contradictory information about their acute influence on myocardium. The aim of this study was to examine the acute effects of nandrolone decanoate (ND) on cardiodynamics and coronary flow in isolated rat heart. The hearts of male Wistar albino rats (n = 48, 12 per group, age 8 weeks, body mass 180-200 g) were excised and perfused according to the Langendorff technique at gradually increased coronary perfusion pressures (40-120 cmH2O). After the control sets of experiments, the hearts in different groups were perfused with different doses of ND (1, 10, or 100 µmol/L separately). Using a sensor placed in the left ventricle, we registered maximum and minimum rate of pressure development in the left ventricle (dP/dtmax and dP/dtmin), systolic and diastolic left ventricular pressure (SLVP and DLVP), and heart rate (HR). Coronary flow (CF) was measured flowmetrically. The results clearly show the depression in cardiac function caused by higher doses of ND. The highest concentration of ND (100 µmol/L) induced the most deleterious impact on the myocardial function and perfusion of the heart (coronary circulation), which could be of clinical significance. © 2016, Canadian Science Publishing. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats(2023) ;Bajic, Zorislava (57211522032) ;Sobot, Tanja (57008142200) ;Uletilovic, Snezana (16319943200) ;Mandic-Kovacevic, Nebojsa (58131076900) ;Cvjetkovic, Tanja (58131512500) ;Malicevic, Ugljesa (58192841400) ;Djukanovic, Djordje (58248405300) ;Duran, Mladen (58248422100) ;Vesic, Nikolina (58248366900) ;Avram, Sanja (40560915000) ;Jovicic, Sanja (58131408000) ;Katana, Maja (58248405400) ;Matavulj, Amela (8295596800) ;Ponorac, Nenad (13612805400) ;Djuric, Dragan M. (36016317400) ;Stojiljkovic, Milos P. (7003831355)Skrbic, Ranko (6506440995)Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular disease, especially myocardial injury. Due to their hy[1]poglycemic effects, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are efficiently used for T2DM management. GLP[1]1RAs also have anti-inflammatory and antioxidative effects and can improve cardiac function. The aim of this study was to investigate the cardioprotective effects of liraglutide, a GLP-1RA, on isoprenaline-induced myocardial injury in rats. The study included four groups of animals. They were pretreated with saline for 10 days + saline on days 9 and 10 (control), saline for 10 days + isoprenaline on days 9 and 10 (isoprenaline group), liraglutide for 10 days + saline on days 9 and 10 (liraglutide group), and liraglutide for 10 days, and on days 9 and 10 isoprenaline was administered. This study evaluated ECG, myocar[1]dial injury markers, oxidative stress markers, and pathohistological changes. The results showed that liraglutide mitigated the isoprenaline-induced cardiac dysfunction recorded by ECG. Liraglutide reduced serum markers of myocardial injury such as high-sensitive troponin I, aspartate aminotransferase, alanine aminotransferase, reduced thiobarbituric acid reactive sub[1]stances, increased catalase and superoxide dismutase activity, increased reduced glutathione level, and improved lipid profile. Liraglutide induced antioxidative protection and alleviated isoprenaline-induced myocardial injury. © 2023, Canadian Science Publishing. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats(2023) ;Bajic, Zorislava (57211522032) ;Sobot, Tanja (57008142200) ;Uletilovic, Snezana (16319943200) ;Mandic-Kovacevic, Nebojsa (58131076900) ;Cvjetkovic, Tanja (58131512500) ;Malicevic, Ugljesa (58192841400) ;Djukanovic, Djordje (58248405300) ;Duran, Mladen (58248422100) ;Vesic, Nikolina (58248366900) ;Avram, Sanja (40560915000) ;Jovicic, Sanja (58131408000) ;Katana, Maja (58248405400) ;Matavulj, Amela (8295596800) ;Ponorac, Nenad (13612805400) ;Djuric, Dragan M. (36016317400) ;Stojiljkovic, Milos P. (7003831355)Skrbic, Ranko (6506440995)Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular disease, especially myocardial injury. Due to their hy[1]poglycemic effects, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are efficiently used for T2DM management. GLP[1]1RAs also have anti-inflammatory and antioxidative effects and can improve cardiac function. The aim of this study was to investigate the cardioprotective effects of liraglutide, a GLP-1RA, on isoprenaline-induced myocardial injury in rats. The study included four groups of animals. They were pretreated with saline for 10 days + saline on days 9 and 10 (control), saline for 10 days + isoprenaline on days 9 and 10 (isoprenaline group), liraglutide for 10 days + saline on days 9 and 10 (liraglutide group), and liraglutide for 10 days, and on days 9 and 10 isoprenaline was administered. This study evaluated ECG, myocar[1]dial injury markers, oxidative stress markers, and pathohistological changes. The results showed that liraglutide mitigated the isoprenaline-induced cardiac dysfunction recorded by ECG. Liraglutide reduced serum markers of myocardial injury such as high-sensitive troponin I, aspartate aminotransferase, alanine aminotransferase, reduced thiobarbituric acid reactive sub[1]stances, increased catalase and superoxide dismutase activity, increased reduced glutathione level, and improved lipid profile. Liraglutide induced antioxidative protection and alleviated isoprenaline-induced myocardial injury. © 2023, Canadian Science Publishing. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Carotid enlargement and serum levels of von Willebrand factor in rheumatoid arthritis: A follow-up study(2012) ;Veselinovic, Mirjana (54418120000) ;Jakovljevic, Vladimir (56425747600) ;Jurisic-Skevin, Aleksandra (37072707300) ;Toncev, Slavco (19036719400)Djuric, Dragan M. (36016317400)This follow-up study aimed to evaluate the relationship between serum levels of von Willebrand factor (vWf) and common carotid intima-media thickness (IMT) in patients with rheumatoid arthritis (RA). In the initial assessment, 34 female rheumatoid arthritis patients and 30 sex- and age-matched controls were included. The relationship among vWf serum levels, cardiovascular risk factors, and inflammation was initially assessed. The effects of these variables on carotid IMT were evaluated 5 years later. There were no significant differences between the RA patients and the controls in terms of IMT at the first evaluation. Five years later, the carotid IMT increased more significantly in RA patients if compared to controls (p<0.001). The progression of carotid IMT significantly correlated with erythrocyte sedimentation rate (ESR) (r=0.368, p=0.032) and Creactive protein (r=0.506, p=0.002). The progression of carotid IMT did not significantly correlate with vWf serum levels in the RA patients, although, at initial and repeated measurements, it showed statistically higher values of vWF in the RA patients compared to the control group (p<0.01). The RA patients displayed accelerated development of atherosclerosis, as indicated by the increased IMT of carotid artery. Increased serum levels of vWF may suggest its potential role in cardiovascular risk prediction in RA patients. © Clinical Rheumatology 2012. - Some of the metrics are blocked by yourconsent settings
Publication Do dynamic changes in haematological and biochemical parameters predict mortality in critically ill COVID-19 patients?(2024) ;Jandric, Milka (57214108236) ;Zlojutro, Biljana (46061719400) ;Momcicevic, Danica (56690345100) ;Dragic, Sasa (56690301200) ;Kovacevic, Tijana (56689986900) ;Djajic, Vlado (6508151347) ;Stojiljkovic, Milos P. (7003831355) ;Loncar-Stojiljkovic, Dragana (6508357052) ;Skrbic, Ranko (6506440995) ;Djuric, Dragan M. (36016317400)Kovacevic, Pedja (55377814500)BACKGROUND: Critically ill COVID-19 patients are usually subjected to clinical, laboratory, and radiological diagnostic procedures resulting in numerous findings. Utilizing these findings as indicators for disease progression or outcome prediction is particularly intriguing. OBJECTIVES: Exploring the significance of dynamic changes in haematological and biochemical parameters in predicting the mortality of critically ill COVID-19 patients. METHODS: The present study was a prospective and observational study involving mechanically ventilated 75 critically ill adult COVID-19 patients with hypoxemic respiratory failure. The collected data included baseline patient characteristics, treatment options, outcome, and laboratory findings at admission and 7 days after. The dynamics of the obtained findings were compared between survivors and non-survivors. RESULTS: The 28-day survival rate was 61.3%. In the group of non-survivors significant dynamic changes were found for C-reactive protein (p= 0.001), interleukin-6 (p< 0.001), lymphocyte (p= 0.003), neutrophil-lymphocyte ratio (p= 0.003), platelets (p< 0.001), haemoglobin (p< 0.001), iron (p= 0.012), and total iron-binding capacity (p< 0.001). Statistically significant changes over time were found for ferritin (p= 0.010), D-dimer (p< 0.001), hs-troponin T (p< 0.002), lactate dehydrogenase (p= 0.001), glucose (p= 0.023), unsaturated iron-binding capacity (p= 0.008), and vitamin D (p< 0.001). CONCLUSION: The dynamic changes in inflammatory, haematological and biochemical parameters can predict disease severity, and outcome. © 2025 - IOS Press. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Do dynamic changes in haematological and biochemical parameters predict mortality in critically ill COVID-19 patients?(2024) ;Jandric, Milka (57214108236) ;Zlojutro, Biljana (46061719400) ;Momcicevic, Danica (56690345100) ;Dragic, Sasa (56690301200) ;Kovacevic, Tijana (56689986900) ;Djajic, Vlado (6508151347) ;Stojiljkovic, Milos P. (7003831355) ;Loncar-Stojiljkovic, Dragana (6508357052) ;Skrbic, Ranko (6506440995) ;Djuric, Dragan M. (36016317400)Kovacevic, Pedja (55377814500)BACKGROUND: Critically ill COVID-19 patients are usually subjected to clinical, laboratory, and radiological diagnostic procedures resulting in numerous findings. Utilizing these findings as indicators for disease progression or outcome prediction is particularly intriguing. OBJECTIVES: Exploring the significance of dynamic changes in haematological and biochemical parameters in predicting the mortality of critically ill COVID-19 patients. METHODS: The present study was a prospective and observational study involving mechanically ventilated 75 critically ill adult COVID-19 patients with hypoxemic respiratory failure. The collected data included baseline patient characteristics, treatment options, outcome, and laboratory findings at admission and 7 days after. The dynamics of the obtained findings were compared between survivors and non-survivors. RESULTS: The 28-day survival rate was 61.3%. In the group of non-survivors significant dynamic changes were found for C-reactive protein (p= 0.001), interleukin-6 (p< 0.001), lymphocyte (p= 0.003), neutrophil-lymphocyte ratio (p= 0.003), platelets (p< 0.001), haemoglobin (p< 0.001), iron (p= 0.012), and total iron-binding capacity (p< 0.001). Statistically significant changes over time were found for ferritin (p= 0.010), D-dimer (p< 0.001), hs-troponin T (p< 0.002), lactate dehydrogenase (p= 0.001), glucose (p= 0.023), unsaturated iron-binding capacity (p= 0.008), and vitamin D (p< 0.001). CONCLUSION: The dynamic changes in inflammatory, haematological and biochemical parameters can predict disease severity, and outcome. © 2025 - IOS Press. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Dynamic changes in coagulation, hematological and biochemical parameters as predictors of mortality in critically ill COVID-19 patients: A prospective observational study(2022) ;Zlojutro, Biljana (46061719400) ;Jandric, Milka (57214108236) ;Momcicevic, Danica (56690345100) ;Dragic, Sasa (56690301200) ;Kovacevic, Tijana (56689986900) ;Djajic, Vlado (6508151347) ;Stojiljkovic, Milos P. (7003831355) ;Skrbic, Ranko (6506440995) ;Djuric, Dragan M. (36016317400)Kovacevic, Pedja (55377814500)INTRODUCTION: This study was created to analyze dynamic alterations in coagulation, hematological and biochemical parameters and their association with mortality of COVID-19 patients. To identify the most sensitive biomarkers as predictors of mortality more research is required. METHODS: The present study was a prospective, one-year-long observational study conducted on all critically ill, COVID-19 patients with respiratory failure. The following data were collected: demographic and clinical characteristics of the study population, comorbidities, coagulation, biochemical and hematological parameters. The primary outcome was the proportion of patients who died. RESULTS: 91 patients with median age 60 (50-67), 76.9% male, met the acute respiratory distress syndrome criteria. It was tested whether dynamic change (delta-Δ) of parameters that were found to be predictors of mortality is independently associated with poor outcome. Adjusted (multivariate) analysis was used, where tested parameters were corrected for basic and clinical patients characteristics. The only inflammatory parameter which dynamic change had statistically significant odds ratio was ΔCRP (p < 0.005), while among coagulation parameters statistically significant OR was found for Δ fibrinogen (p < 0.005) in predicting mortality. CONCLUSION: Monitoring of coagulation, hematological and biochemical parameters abnormalities and their dynamical changes can potentially improve management and predict mortality in critically ill COVID -19 patients. © 2023 - IOS Press. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Dynamic changes in coagulation, hematological and biochemical parameters as predictors of mortality in critically ill COVID-19 patients: A prospective observational study(2022) ;Zlojutro, Biljana (46061719400) ;Jandric, Milka (57214108236) ;Momcicevic, Danica (56690345100) ;Dragic, Sasa (56690301200) ;Kovacevic, Tijana (56689986900) ;Djajic, Vlado (6508151347) ;Stojiljkovic, Milos P. (7003831355) ;Skrbic, Ranko (6506440995) ;Djuric, Dragan M. (36016317400)Kovacevic, Pedja (55377814500)INTRODUCTION: This study was created to analyze dynamic alterations in coagulation, hematological and biochemical parameters and their association with mortality of COVID-19 patients. To identify the most sensitive biomarkers as predictors of mortality more research is required. METHODS: The present study was a prospective, one-year-long observational study conducted on all critically ill, COVID-19 patients with respiratory failure. The following data were collected: demographic and clinical characteristics of the study population, comorbidities, coagulation, biochemical and hematological parameters. The primary outcome was the proportion of patients who died. RESULTS: 91 patients with median age 60 (50-67), 76.9% male, met the acute respiratory distress syndrome criteria. It was tested whether dynamic change (delta-Δ) of parameters that were found to be predictors of mortality is independently associated with poor outcome. Adjusted (multivariate) analysis was used, where tested parameters were corrected for basic and clinical patients characteristics. The only inflammatory parameter which dynamic change had statistically significant odds ratio was ΔCRP (p < 0.005), while among coagulation parameters statistically significant OR was found for Δ fibrinogen (p < 0.005) in predicting mortality. CONCLUSION: Monitoring of coagulation, hematological and biochemical parameters abnormalities and their dynamical changes can potentially improve management and predict mortality in critically ill COVID -19 patients. © 2023 - IOS Press. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Editorial: Nutritional Intervention in Cardiovascular Diseases: From Basic Science to Applied Investigations(2022) ;Jakovljevic, Vladimir Lj. (56425747600) ;Djuric, Dragan M. (36016317400)Dhalla, Naranjan S. (57208169674)[No abstract available] - Some of the metrics are blocked by yourconsent settings
Publication Editorial: Nutritional Intervention in Cardiovascular Diseases: From Basic Science to Applied Investigations(2022) ;Jakovljevic, Vladimir Lj. (56425747600) ;Djuric, Dragan M. (36016317400)Dhalla, Naranjan S. (57208169674)[No abstract available] - Some of the metrics are blocked by yourconsent settings
Publication Effect of folic acid on isoprenaline-induced myocardial injury in rats(2024) ;Sobot, Tanja (57008142200) ;Bajic, Zorislava (57211522032) ;Skrbic, Ranko (6506440995) ;Uletilovic, Snezana (16319943200) ;Mandic-Kovacevic, Nebojsa (58131076900) ;Cvjetkovic, Tanja (58131512500) ;Malicevic, Ugljesa (58192841400) ;Djukanovic, Djordje (58248405300) ;Bojic, Milica Gajic (57222586867) ;Jovicic, Sanja (58131408000) ;Barudzija, Maja (58871662800) ;Stojiljkovic, Milos P. (7003831355)Djuric, Dragan M. (36016317400)Background: Isoprenaline (ISO), a synthetic catecholamine and a β-adrenoceptor agonist, is widely used to develop an experimental model of myocardial injury (MI) in rats. The leading hypothesis for ISO-induced MI in rats is that it results from catecholamine overstimulation, oxidative stress, inflammatory responses, and development of cardiomyopathy during ISO administration. Folic acid (FA) reduces oxidative stress, improves endothelial function and prevents apoptosis, thereby contributing to cardiovascular protection. This study aimed to investigate the potentially protective effect of FA pretreatment on ISO-induced MI in rats. Methods: For 7 days, adult male Wistar albino rats were pretreated with 5 mg/kg/day of FA. On the sixth and seventh days, MI in rats was induced by administering 85 mg/kg/day of ISO. Prooxidant markers in plasma samples, antioxidant capacity in erythrocyte lysates, cardiac damage markers, lipid profile, electrocardiography (ECG) and histopathological analysis were evaluated. Results: FA pretreatment significantly alleviated changes induced by ISO; it decreased the homocysteine and high-sensitivity troponin I level. FA moderately decreased the reactive oxygen species (ROS) levels (superoxide anion radical, hydrogen peroxide and thiobarbituric acid reactive substances) and improved the antioxidant activities of catalase, superoxide dismutase and reduced glutathione. ISO reduced the nitrite level and FA significantly alleviated this change. Conclusion: It can be concluded that FA, as a mild antioxidant, could be an appropriate cardioprotective substance in the rat model of ISO-induced MI. © 2023 Akadémiai Kiadó, Budapest. - Some of the metrics are blocked by yourconsent settings
Publication Efficiency of atorvastatin and simvastatin in improving cardiac function during the different degrees of hyperhomocysteinemia(2018) ;Nikolic Turnic, Tamara R. (56425849500) ;Jakovljevic, Vladimir Lj. (56425747600) ;Djuric, Dragan M. (36016317400) ;Jeremic, Nevena S. (56609154900) ;Jeremic, Jovana N. (56728450400) ;Milosavljevic, Isidora M. (55696426400) ;Srejovic, Ivan M. (55754581700) ;Selakovic, Dragica V. (55754805500)Zivkovic, Vladimir I. (55352337400)The aim of this study was to assess the impact of atorvastatin and simvastatin on myocardial contractility during the different degrees of hyperhomocysteinemia (HHcy) in rats. Study was conducted on adult male Wistar albino rats (n = 90; 4 weeks old; 100 ± 15 g body mass) in which HHcy was achieved by dietary manipulation. Animals were exposed to pharmacology treatment with atorvastatin in dose of 3 mg/kg per day i.p. or simvastatin in dose of 5 mg/kg per day i.p. at the same time every day, according to equivalent therapeutic doses of these statins (10 mg atorvastatin = 20 mg simvastatin). After the dietary manipulation and pharmacological treatment and confirmation of HHcy, all animals were sacrificed, hearts were isolated, and cardiac function was tested according to the Langendorff technique. Size of recovery of maximum rate of left ventricular development (dp/dtmax), minimum rate of left ventricular development (dp/dtmin), systolic left ventricular development, diastolic left ventricular development, heart rate, and coronary flow at the 40, 60, 80, 100, and 120 cmH2O coronary perfusion pressure were measured in state of physiological condition (homocysteine less than 15 μmol/L), mild HHcy, and moderate HHcy. Atorvastatin treatment significantly attenuated homocysteine-induced impairment of myocyte contractility and dominantly decreased dp/dtmax, dp/dtmin, and heart rate and induced greater changes in systolic left ventricular development compared with simvastatin. Treatment with atorvastatin seems able to revert systolic abnormalities and improve contractility during the different degrees of HHcy. © 2018, Canadian Science Publishing. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Efficiency of atorvastatin and simvastatin in improving cardiac function during the different degrees of hyperhomocysteinemia(2018) ;Nikolic Turnic, Tamara R. (56425849500) ;Jakovljevic, Vladimir Lj. (56425747600) ;Djuric, Dragan M. (36016317400) ;Jeremic, Nevena S. (56609154900) ;Jeremic, Jovana N. (56728450400) ;Milosavljevic, Isidora M. (55696426400) ;Srejovic, Ivan M. (55754581700) ;Selakovic, Dragica V. (55754805500)Zivkovic, Vladimir I. (55352337400)The aim of this study was to assess the impact of atorvastatin and simvastatin on myocardial contractility during the different degrees of hyperhomocysteinemia (HHcy) in rats. Study was conducted on adult male Wistar albino rats (n = 90; 4 weeks old; 100 ± 15 g body mass) in which HHcy was achieved by dietary manipulation. Animals were exposed to pharmacology treatment with atorvastatin in dose of 3 mg/kg per day i.p. or simvastatin in dose of 5 mg/kg per day i.p. at the same time every day, according to equivalent therapeutic doses of these statins (10 mg atorvastatin = 20 mg simvastatin). After the dietary manipulation and pharmacological treatment and confirmation of HHcy, all animals were sacrificed, hearts were isolated, and cardiac function was tested according to the Langendorff technique. Size of recovery of maximum rate of left ventricular development (dp/dtmax), minimum rate of left ventricular development (dp/dtmin), systolic left ventricular development, diastolic left ventricular development, heart rate, and coronary flow at the 40, 60, 80, 100, and 120 cmH2O coronary perfusion pressure were measured in state of physiological condition (homocysteine less than 15 μmol/L), mild HHcy, and moderate HHcy. Atorvastatin treatment significantly attenuated homocysteine-induced impairment of myocyte contractility and dominantly decreased dp/dtmax, dp/dtmin, and heart rate and induced greater changes in systolic left ventricular development compared with simvastatin. Treatment with atorvastatin seems able to revert systolic abnormalities and improve contractility during the different degrees of HHcy. © 2018, Canadian Science Publishing. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Lipid lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel(2017) ;Cicero, Arrigo F.G. (7003403707) ;Colletti, Alessandro (56538296200) ;Bajraktari, Gani (12764374400) ;Descamps, Olivier (6701764714) ;Djuric, Dragan M. (36016317400) ;Ezhov, Marat (57218254057) ;Fras, Zlatko (35615293100) ;Katsiki, Niki (25421628400) ;Langlois, Michel (56355464300) ;Latkovskis, Gustavs (6507756746) ;Panagiotakos, Demosthenes B. (7005977027) ;Paragh, Gyorgy (7003269524) ;Mikhailidis, Dimitri P. (36042757800) ;Mitchenko, Olena (57193516360) ;Paulweber, Bernhard (36519500600) ;Pella, Daniel (57207570055) ;Pitsavos, Christos (35399739300) ;Reiner, Željko (55411641000) ;Ray, Kausik K. (35303190300) ;Rizzo, Manfredi (7202023733) ;Sahebkar, Amirhossein (26639699900) ;Serban, Maria-Corina (56497645100) ;Sperling, Laurence S. (56785421900) ;Toth, Peter P. (7102285226) ;Vinereanu, Dragos (6603080279) ;Vrablík, Michal (6701669648) ;Wong, Nathan D. (7202836669)Banach, Maciej (22936699500)[No abstract available] - Some of the metrics are blocked by yourconsent settings
Publication Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel(2017) ;Cicero, Arrigo F.G. (7003403707) ;Colletti, Alessandro (56538296200) ;Bajraktari, Gani (12764374400) ;Descamps, Olivier (6701764714) ;Djuric, Dragan M. (36016317400) ;Ezhov, Marat (57218254057) ;Fras, Zlatko (35615293100) ;Katsiki, Niki (25421628400) ;Langlois, Michel (56355464300) ;Latkovskis, Gustavs (6507756746) ;Panagiotakos, Demosthenes B. (7005977027) ;Paragh, Gyorgy (7003269524) ;Mikhailidis, Dimitri P. (36042757800) ;Mitchenko, Olena (57193516360) ;Paulweber, Bernhard (36519500600) ;Pella, Daniel (57207570055) ;Pitsavos, Christos (35399739300) ;Reiner, Željko (55411641000) ;Ray, Kausik K. (35303190300) ;Rizzo, Manfredi (7202023733) ;Sahebkar, Amirhossein (26639699900) ;Serban, Maria-Corina (56497645100) ;Sperling, Laurence S. (56785421900) ;Toth, Peter P. (7102285226) ;Vinereanu, Dragos (6603080279) ;Vrablík, Michal (6701669648) ;Wong, Nathan D. (7202836669)Banach, Maciej (22936699500)In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipidlowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting. © The Author(s) 2017. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Liraglutide Protects Cardiomyocytes against Isoprenaline-Induced Apoptosis in Experimental Takotsubo Syndrome(2024) ;Bajic, Zorislava (57211522032) ;Sobot, Tanja (57008142200) ;Amidzic, Ljiljana (6506935672) ;Vojinovic, Natasa (57208879045) ;Jovicic, Sanja (58131408000) ;Gajic Bojic, Milica (57222586867) ;Djuric, Dragan M. (36016317400) ;Stojiljkovic, Milos P. (7003831355) ;Bolevich, Sergey (6603144931)Skrbic, Ranko (6506440995)Takotsubo syndrome (TTS) is a stress-induced cardiomyopathy, characterized by an increased concentration of catecholamines, free radicals, and inflammatory cytokines, endothelial dysfunction, and increased apoptotic activity. High doses of isoprenaline are used in animal models to induce Takotsubo (TT)-like myocardial injury. The aim of the study was to investigate the antiapoptotic effects of liraglutide in experimental TTS and its role in the NF-κB pathway. Wistar rats were pretreated with liraglutide for 10 days, and on days 9 and 10, TT-like myocardial injury was induced with isoprenaline. After the sacrifice on day 11, hearts were isolated for histopathological and immunohistochemical analysis. Liraglutide reduced isoprenaline-induced cardiomyocyte apoptosis by decreasing cleaved caspase-3 (CC3), BCL-2-associated X protein (BAX), and NF-κB and increasing B-cell lymphoma/leukemia-2 (BCL-2). An increase in NF-κB in isoprenaline-treated rats was in positive correlation with proapoptotic markers (BAX and CC3) and in negative correlation with antiapoptotic marker BCL-2. Liraglutide increased BCL-2 and decreased NF-κB, BAX, and CC3, preserving the same correlations of NF-κB to apoptotic markers. It is concluded that liraglutide protects cardiomyocytes against isoprenaline-induced apoptosis in experimental TT-like myocardial injury through downregulation of the NF-κB pathway. © 2024 by the authors. - Some of the metrics are blocked by yourconsent settings
Publication Liraglutide Protects Cardiomyocytes against Isoprenaline-Induced Apoptosis in Experimental Takotsubo Syndrome(2024) ;Bajic, Zorislava (57211522032) ;Sobot, Tanja (57008142200) ;Amidzic, Ljiljana (6506935672) ;Vojinovic, Natasa (57208879045) ;Jovicic, Sanja (58131408000) ;Gajic Bojic, Milica (57222586867) ;Djuric, Dragan M. (36016317400) ;Stojiljkovic, Milos P. (7003831355) ;Bolevich, Sergey (6603144931)Skrbic, Ranko (6506440995)Takotsubo syndrome (TTS) is a stress-induced cardiomyopathy, characterized by an increased concentration of catecholamines, free radicals, and inflammatory cytokines, endothelial dysfunction, and increased apoptotic activity. High doses of isoprenaline are used in animal models to induce Takotsubo (TT)-like myocardial injury. The aim of the study was to investigate the antiapoptotic effects of liraglutide in experimental TTS and its role in the NF-κB pathway. Wistar rats were pretreated with liraglutide for 10 days, and on days 9 and 10, TT-like myocardial injury was induced with isoprenaline. After the sacrifice on day 11, hearts were isolated for histopathological and immunohistochemical analysis. Liraglutide reduced isoprenaline-induced cardiomyocyte apoptosis by decreasing cleaved caspase-3 (CC3), BCL-2-associated X protein (BAX), and NF-κB and increasing B-cell lymphoma/leukemia-2 (BCL-2). An increase in NF-κB in isoprenaline-treated rats was in positive correlation with proapoptotic markers (BAX and CC3) and in negative correlation with antiapoptotic marker BCL-2. Liraglutide increased BCL-2 and decreased NF-κB, BAX, and CC3, preserving the same correlations of NF-κB to apoptotic markers. It is concluded that liraglutide protects cardiomyocytes against isoprenaline-induced apoptosis in experimental TT-like myocardial injury through downregulation of the NF-κB pathway. © 2024 by the authors. - Some of the metrics are blocked by yourconsent settings
Publication Methodological challenges in using human umbilical artery as a model for in vitro studies(2023) ;Gajić Bojić, Milica (57222586867) ;Đukanović, Đorđe (57898260000) ;Marinković, Sonja (57578788200) ;Jovičić, Sanja (58131408000) ;Stojiljković, Miloš P. (7003831355) ;Djuric, Dragan M. (36016317400)Škrbić, Ranko (6506440995)New Findings: What is the central question of this study? What are the biggest challenges in performing in vitro studies on isolated human umbilical arteries? What is the main finding and its importance? The protocols presented in this study indicate some potential outcomes important for interpretation of the vascular responsivities of human umbilical arteries and could be useful for planning future in vitro studies with human umbilical arteries. Abstract: Human umbilical artery (HUA) preparations are of particular importance for in vitro studies on isolated blood vessels because their sampling is not risky for the patient, and they can provide the closest possible impression of changes related to the uteroplacental circulation during pre-eclampsia. Using organ bath techniques, useful experimental protocols are provided for measuring some pathophysiological phenomena in the vascular responses of HUAs. Several vasoconstrictors (serotonin, prostaglandin F and phenylephrine) and vasodilators (acetylcholine and minoxidil) were seleted for determination of their vasoactivity in HUAs. The role of L-type voltage-operated calcium channels and different types of potassium channels (KATP, BKCa and KV) were assessed, as was the impact of homocysteine. Serotonin was confirmed to be the most potent vasoconstrictor, while acetylcholine and phenylephrine caused variability in the relaxation and contraction response of HUA, respectively. The observed increase in serotonin-induced contraction and a decrease in minoxidil-induced relaxation in the presence of homocysteine suggested its procontractile effect on HUA preparations. Using selective blockers, it was determined that KATP and KV channels participate in the minoxidil-induced relaxation, while L-type voltage-dependent Ca2+ channels play an important role in the serotonin-induced contraction. The presented protocols reveal some of the methodological challenges related to HUA preparations and indicate potential outcomes in interpreting the vascular effects of the investigated substances, both in physiological conditions and in the homocysteine-induced pre-eclampsia model. © 2023 The Authors. Experimental Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
